The core clinical implication of targeting the LRP5/LIMA1/MYO5B axis lies in its dual efficacy: simultaneously inhibiting metastatic tumor growth and repairing tumor-induced bone destruction, ultimately restoring a healthier bone microenvironment—an outcome that is difficult to achieve with single-agent cytotoxic or anti-resorptive therapies [43]. Here, LIMA1 is linked to neoplasm.